FDA seeking input on disclosing interim CV outcomes data

FDA will hold a public hearing on Aug. 11 to discuss the confidentiality of interim data for cardiovascular outcomes trials that are ongoing at the time the agency approves a drug. The agency is seeking stakeholder input on the potential effects of disclosing information or analyses from ongoing CV outcomes trials, including what interim data "represent the greatest risk to trial integrity or jeopardize trial continuation." ...